Novartis twin drug setbacks pile pressure on pipeline and CEO
Novartis announced on Tuesday that its experimental drug for a muscle-wasting disorder failed a late-stage study, marking the second major setback in a short period. The drug, del-desiran, acquired through Novartis's $12 billion acquisition of Avidity, experienced this failure while being tested in myotonic dystrophy, a condition without approved treatments.
Analysts and shareholders expressed concern over the impact of this setback on Novartis's pipeline and CEO Vas Narasimhan's M&A strategy. The news led to a significant 9% drop in Novartis's shares, signaling one of its worst trading days. This recent failure adds pressure on Novartis to secure other drugs in development and uphold its full-year growth expectations.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drug endpoints.news
- STAT+: Neuromuscular drug from Novartis fails in key study, adding to pressure on company statnews.com
- Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff marketwatch.com
- Pharma major Novartis falls nearly 10%, heading for worst day on record after three drug trial setbacks cnbc.com
- Novartis extends selloff as Deutsche Bank cuts on twin drug trial setbacks seekingalpha.com
